HSV Infection
Conditions
Brief summary
Randomized, open-label, multi-center, comparative trial to assess the efficacy and safety in immunocompromised subjects with acyclovir resistant or acyclovir susceptible mucocutaneous HSV infection, treated with pritelivir 100 mg once daily (following a loading dose of 400 mg as first dose to rapidly reach steady-state plasma concentration) or investigators choice, which can be either foscarnet 40 mg/kg every 8 hours or 60 mg/kg every 12 hours, or Cidofovir iv 5 mg/kg body weight given once weekly, or Cidofovir 1% or 3% topical applied 2 to 4 times daily, or Imiquimod 5% topical 3 times per week) (provided the drug is nationally approved).
Detailed description
The trial comprises 5 Parts, Part A, B, C, D, E and F. Part A and Part B (Phase 2) have been finalised. * Part A is a randomized, open-label, multi-center, comparative design to assess the efficacy and safety in subjects with ACV-resistant mucocutaneous HSV infection, treated with oral pritelivir or intravenous foscarnet. * Part B is an open-label, multi-center design to assess the efficacy and safety of pritelivir in subjects with ACV-resistant-mucocutaneous HSV and who either: 1. present with foscarnet-resistance/intolerance, or 2. developed foscarnet resistance/intolerance during treatment in Part A (no improvement after at least 5 days of foscarnet therapy or intolerance to foscarnet requiring cessation of foscarnet treatment). Parts C, D, E and F (Phase 3). * Part C is a randomized, open-label, multi-center, comparative design to assess the efficacy and safety of oral pritelivir in subjects with acyclovir resistent (ACV-R) mucocutaneous HSV episodes. Subjects with ACV-R mucocutaneous HSV infection will be randomized 1:1 to receive either oral pritelivir or Investigator's Choice. This trial part is designed to show superiority of pritelivir against Investigator's Choice in obtaining clinical cure, ie, number of subjects with all lesions healed within 28 days. * Part D is an open-label, multi-center design to assess the efficacy and safety of pritelivir in subjects with ACV-R mucocutaneous HSV episodes and who in addition either: 1. present with iv foscarnet resistance/intolerance already at Screening for inclusion, or 2. developed foscarnet resistance/intolerance during treatment in Part C (no improvement after at least 7 days of foscarnet treatment or intolerance to foscarnet requiring cessation of foscarnet treatment). Part D has been closed in June 2022. * Part E is an open-label, multi-center design to assess the safety and efficacy of pritelivir in subjects with acyclovir susceptible (ACV-S) mucocutaneous HSV episodes, (Part E is not being conducted in Germany). * Part F is an open-label, multi-center design to assess the efficacy and safety of pritelivir in subjects with ACV-R mucocutaneous HSV episodes and who in addition either: 1. present with iv foscarnet resistance/intolerance already at Screening for inclusion, or 2. developed foscarnet resistance/intolerance during treatment in Part C (no improvement after at least 7 days of foscarnet treatment or intolerance to foscarnet requiring cessation of foscarnet treatment). 3. cannot be enrolled into Part D anymore because enrollment into Part D has been completed. Dosing of trial medication: Pritelivir oral tablet as single daily doses of 100 mg (following a loading dose of 400 mg as first dose) Comparator per investigator's choice (provided the drug listed below is nationally approved): Foscarnet intermittent infusions of 40 mg/kg every 8 hours or 60 mg/kg every 12 hours (to be adjusted in case of renal impairment) for a minimum of 1 hour duration, or Cidofovir iv infusion of 5 mg/kg body weight given once weekly, or Cidofovir 1% or 3% topical treatment, applied 2 to 4 times daily, or Imiquimod 5% topical treatment, 3 times per week. Duration of treatment: Until all mucocutaneous HSV lesions are healed or up to 28 days, whichever is earlier. A prolongation up to a maximum of 42 days may be possible depending on the clinical progress.
Interventions
DRUGPritelivir
100 mg oral tablets
Foscarnet iv, 40 mg/kg BW tid or 60mg/kg bid or Cidofovir iv, 5 mg/kg BW given once weekly or Cidofovir 1% or 3%, topically applied 2 to 4 times daily or Imiquimod 5%, Solution for iv infusion or topical application
Sponsors
AiCuris Anti-infective Cures AG
Medpace, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Part C inclusion criteria 1. Immunocompromised men and women of any ethnic group aged ≥16 years. In Canada, Germany, Belgium: Immunocompromised (due to conditions including but not limited to HIV infection, hematopoietic cell or solid organ transplantation, and chronic use of immunosuppressive treatment) men and women of any ethnic group aged \>18 years. 2. ACV-R mucocutaneous HSV infection based on clinical failure or positive genotypic/phenotypic ACV resistance testing for current lesion. Clinical failure is defined as no improvement after oral or iv doses for at least 7 days at doses equivalent to or greater than the local agency approved high oral doses of acyclovir, valacyclovir or famciclovir. 3. Lesions accessible for visual inspection to allow assessment of lesion healing including visualization by endoscopy. 4. Willingness to use highly effective birth control. 5. Subject, and/or their legally authorized representative, (proxy consent is not permitted in Germany), must be willing and able to understand the Informed Consent Form. 6. Negative serum β-HCG (beta-human chorionic gonadotropin) test for women of child-bearing potential at Screening and a negative urine pregnancy test at Day 1. 7. Written informed consent. For subjects, who are unable to provide informed consent for whatever reason, written consent must be obtained from the legal representative, (proxy consent is not permitted in Germany). Part D and F inclusion criteria All inclusion criteria as for Part C, except for inclusion criterion 2, which is replaced by: 2\. ACV-R and foscarnet-R mucocutaneous HSV infection based on clinical failure or positive genotypic/phenotypic resistance testing for current lesion or documented intolerance to iv foscarnet requiring cessation of foscarnet treatment or precluding foscarnet treatment. Subjects will be able to enter Part F only after closure of enrollment in Part D. Part E inclusion (Part E is not being conducted in Germany) All inclusion criteria as for Part C, except for inclusion criterion 2, which is replaced by: 2\. Recurrent mucocutaneous HSV infection considered ACV-S. Part C
Exclusion criteria
1. Known resistance/intolerance to pritelivir or any of the excipients. 2. Previous treatment in PRIOH-1. 3. Baseline safety laboratory abnormalities. 4. History or current evidence of gastrointestinal malabsorption which, in the opinion of the Investigator, may affect the extent of absorption of pritelivir. 5. Hemodialysis for any indication and ESRD (eGFR \<15 mL/min; stage 5 CKD) 6. History or current evidence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, hematological, endocrinological, metabolic, neurological, psychiatric, or other relevant diseases. 7. Abnormalities in hematological, clinical chemical or any other laboratory variables. 8. Not able to communicate meaningfully with the Investigator and site staff. 9. Any other condition which in the opinion of the Investigator would interfere with successful completion of this clinical trial. 10. Any other important local condition. 11. Pregnant and/or breastfeeding women. 12. Having received an investigational drug in an investigational drug trial unter certain conditions. Part D (complete)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy measured by cure rate | Up to a maximum of 28 days | Number of subjects cured (all lesions healed as assessed by the Investigator) during the treatment period of up to 28 days relative to the total number of subjects treated with trial medication in the respective treatment group. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy measured by cure rate | Up to a maximum of 42 days | Number of subjects cured (all lesions healed as assessed by the Investigator) during the treatment period of up to 42 days relative to the total number of subjects treated with trial medication in the respective treatment group. |
| Efficacy measured by time to lesion healing | Up to a maximum of 42 days | Time to lesion healing, defined as complete epithelization of the mucocutaneous HSV lesion(s) within the treatment period and no appearance of new lesions, as assessed by the Investigator. |
| Efficacy measured by recurrence rate | At 2 months following post treatment visit, from randomization up to a maximum of 108 days | Recurrence rate at 2 months following PoTV assessed by telephone, defined as number of subjects with a recurrence as assessed by the Investigator following 2/3 months after PoTV relative to the total number of subjects assessed for recurrence at the respective telephone call per treatment. |
| Efficacy measured by pain rate | Up to a maximum of 42 days | Number of days with pain at lesion site relative to the total number of days with analyzable pain data through daily subject self-reporting |
| Efficacy measured by time to pain cessation at site of lesion | Up to a maximum of 42 days | Starting at first dose of trial medication until pain is no longer reported by the subject (date and time) |
| Efficacy measured by average pain score | Up to a maximum of 42 days | Using a single-dimensional scale assessing pain intensity through daily subject self-reporting |
| Efficacy measured by clinical shedding rate | From date of randomization until the date of first documented healing, assessed up to a maximum of 42 days | Number of HSV positive swabs per subject relative to the total number of swabs collected per subject from lesion swabs taken from HSV lesion(s) |
| Efficacy measured by time to cessation of shedding | Up to a maximum of 42 days | Number of days until swabs taken are negative |
| Efficacy measured by mean log number of HSV DNA copies | From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days | Mean log number of HSV DNA copies on HSV DNA positive swabs from lesion(s) as detected by quantitative real-time PCR (polymerase chain reaction). |
| Efficacy measured by resistance to trial medication | From date of randomization until the date of post treatment visit, assessed up to a maximum of 73 days | Resistance to trial medication for lesions not healed within the treatment period or newly appeared lesions under treatment before or at the PoTV. |
| Safety measured by number of subjects developing chronic kidney disease | From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days | Chronic kidney disease |
| Safety measured by percentage of subjects developing chronic kidney disease | From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days | Chronic kidney disease |
| Safety measured by percentage of subjects developing acute Kidney Injury | From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days | Acute Kidney Injury (AKI) stage \>1 of KDIGO (Kidney Disease: Improving Global Outcome) criteria (increase in serum creatinine by 2.0 to 2.9 times compared to baseline or urine output \<0.5 mL/kg/h for \>12 hours) |
| Safety measured by percentage of subjects developing renal impairment | From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days | Renal impairment |
| Safety measured by percentage of subjects developing electrolyte abnormality | From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days | All abnormal values |
| Safety measured by percentage of subjects developing seizures | From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days | All seizures |
| Safety measured by percentage of subjects developing anemia | From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days | Haemoglobin measurement |
| Safety measured by adverse events | From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days | Incidence of Adverse Events |
| Safety measured by haematology | From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days | Incidence of abnormal hematologic laboratory test results |
| Safety measured by lymphadenopathy | From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days | Incidence of lymphadenopathy measured by physical examination |
| Safety measured by CRP (C reactive protein ) | From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days | Incidence of CRP increase |
| Safety measured by cutaneous adverse events | From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days | Incidence of cutaneous adverse events by physical examination |
| Safety measured by (a)PTT (partial thromboplastin time) | From date of randomization until the date of safety follow-up visit, assessed up to a maximum of 73 days | Incidence of (a)PTT increase |
| Safety measured by discontinuation rate | Up to a maximum of 42 days | Number of subjects discontinuing pritelivir or 'Inverstigator's Choice' due to AE(s) or intolerance relative to the total number of subjects treated with pritelivir or foscarnet, respectively |
Countries
Argentina, Australia, Belgium, Canada, France, Georgia, Germany, Greece, Israel, Italy, Mexico, Switzerland, Ukraine, United Kingdom, United States
Outcome results
None listed